Health TrialsbyHealthPanel

Efficacy of Adenosine as Compared to Verapamil in Paroxysmal Supraventricular Tachycardia (pSVT) Patients

ConditionSupraventricular Tachycardia (SVtach)
Trial statusRecruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age18-70
SponsorRashid Latif Medical College

About this trial

Supraventricular tachycardia (SVT) is a term widely used to describe tachycardial dysrhythmias, paroxysmal SVT (PSVT) is a narrow term including only AV nodal re-entrant tachycardia (AVNRT) and atrioventricular re-entrant tachycardia (AVRT), both of which can cause discomfort and, in some cases, life-threatening symptoms.

Usually Carotid sinus massage is done to lower the pulse rate and after the standard time specific verapamil dose is administered. In this study after carotid sinus massage Conventional Valsalva or modified Valsalva maneuver will be randomly applied. In case, the normal sinus rhythm (NSR) is not achieved then verapamil of or adenosine dose will be administered to the patients after after taking the consent.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Stable SVT (not requiring cardioversion, fully conscious, maintaining systolic blood pressure of >90mmHg)

Alert enough and able to give consent

Able to lie flat and non-painful legs during passive leg raising

Disqualifiers

Unstable SVT (Semiconscious, drowsy, breathless, systolic BP <90mmHg)

Not able to give consent

Orthopnea causing inability to lie flat

Atrial fibrillation/atrial flutter

Trial design

Design model

Parallel

Treatments tested in this trial

  • Adenosine

    Drug

    Adenosine is a medication belonging to class V antidysrhythmics, used to treat a type of irregular heart rhythm disorder known as paroxysmal supraventricular tachycardia (PSVT)

  • Verapamil Injection

    Drug

    Verapamil is in a class of medications called calcium-channel blockers. It works by relaxing the blood vessels so the heart does not have to pump as hard. It also increases the supply of blood and oxygen to the heart and slows electrical activity in the heart to control the heart rate.

Treatment groups

210 Participants
are divided into 3 treatment groups
Group A: Group A: Conventional ValsalvaExperimental treatment 1 intervention
Group B: Group B: Modified Valsalva ManeuverExperimental treatment 1 intervention
Group C: Group C: Modified Valsalva ManeuverActive comparator 1 intervention

Trial outcomes

Primary outcomes

1

achieve the normal sinus rhythm

As the patient came to ER blood pressure and primary information will be collected by the in-charge nurse. then treatment will be provided in following steps First; carotid message will be done. Supraventricular tachycardia (SVT) reverted to normal sinus rhythm (NSR), And if NSR not achieved, Vagal maneuver as mentioned in methodology will be performed, And if NSR not achieved, Randomly, IV verapamil or adenosine will be injected. After achieving NSR the patient will be kept under observation for 30 min after that the patient will be asked to visit the Outpatient department (OPD) in the next working day.

Time frame
24 to 36 hours

Secondary outcomes

1

Efficacy of standard or modified vagal maneuver

Frequency of the patients achieved NSR after standard or modified maneuver will be analyzed for efficacy.

Time frame
10 minutes
2

Efficacy of IV verapamil and IV adenosine

carotid message will be done to revert SVT to NSR, Or/And if NSR not achieved Second; Vagal maneuver will be performed, Or/And if NSR not achieved Third, Randomly, IV verapamil or adenosine will be injected in two phases. After achieving NSR the patient will be kept under observation for 30 min.

Time frame
30 to 60 minutes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Rashid Latif Medical College

Lead sponsor

Punjab Institute of Cardology

Collaborator

Himmel Pharmaceutical private limited, Pakistan

Collaborator

Source ClinicalTrials.gov
Apply now